Real-World Persistence on Tofacitinib in Psoriatic Arthritis Patients With Enthesitis: Comments on Recent Findings

REFERENCES

1. 1.↵
   1. Braña I,
   2. Loredo M,
   3. Pardo E,
   4. Burger S,
   5. Fernández-Bretón E,
   6. Queiro R.

   Patients with psoriatic arthritis-related enthesitis and persistence on tofacitinib under real-world conditions. J Rheumatol 2024;51:682-6.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Rodriguez Goicoechea M,
   2. Tejedor Tejada E,
   3. Borrás Blasco J.

   Persistence, current state of the art. Farm Hosp 2023;48:T141.

   OpenUrl
3. 3.↵
   1. De la Cueva Dobao P,
   2. Notario J,
   3. Ferrándiz C, et al

   . Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2019;33:1214-23.

   OpenUrlPubMed
4. 4.↵
   1. Borrás-Blasco J,
   2. Ramírez-Herráiz E,
   3. Navarro Ruiz A.

   [The value of persistence in the 5P Medicine model for chronic diseases]. [Article in Spanish] J Healthc Qual Res 2023;38:345-8.

   OpenUrl
5. 5.↵
   1. Borrás-Blasco J,
   2. Ramírez-Herráiz E,
   3. Navarro-Ruiz A.

   [Influence of adherence on persistence value inside Medicina 6P]. [Article in Spanish] J Healthc Qual Res 2025;40:101123.

   OpenUrlPubMed
6. 6.↵
   1. Borrás-Blasco J,
   2. Ramírez-Herráiz E,
   3. Navarro-Ruiz A.

   Integration of persistence in the 5P-medicine approach for age-related chronic diseases. Int J Qual Health Care 2024;36:mzae026.

   OpenUrlPubMed
7. 7.↵
   1. Valcuende-Rosique A,
   2. Borrás-Blasco J,
   3. Martínez-Badal S,
   4. Cortes X,
   5. Aparicio-Rubio C,
   6. Casterá-Melchor E.

   Evaluation of persistence, retention “rate” and prescription pattern of original infliximab and infliximab CT-P13 in biologic-naïve patients with ulcerative colitis. Farm Hosp 2022;46:296-300.

   OpenUrlPubMed
8. 8.
   1. Borrás-Blasco J,
   2. Cornejo S,
   3. Valcuende-Rosique A, et al

   . Persistence after switching from adalimumab biosimilar RAB11022 to adalimumab biosimilar GP2017 in patients with chronic inflammatory rheumatic diseases. J Pharm Technol 2024; 40:123-30.

   OpenUrl
9. 9.↵
   1. Borrás-Blasco J,
   2. Cornejo S,
   3. Valcuende-Rosique A, et al

   . Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis. Farm Hosp 2025;49:45-52.

   OpenUrl